Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has announced significant progress in its Phase 3 program for HLP003, its lead candidate for major depressive disorder (MDD). The company recently reported business highlights and financial results for the quarter ended June 30, 2026, revealing that enrollment has been completed in APPROACH, the pivotal Phase 3 study evaluating HLP003. Topline data from this study is anticipated in the fourth quarter of 2026, marking a critical milestone for the program.
The APPROACH study is part of the broader PARADIGM program, which also includes the EMBRACE study, currently enrolling participants, and the EXTEND study, which is designed to assess long-term safety and efficacy. The completion of enrollment in APPROACH underscores the company's ability to execute its clinical development strategy. The Phase 3 program is evaluating HLP003 as an adjunctive treatment for MDD, a condition that affects millions worldwide and has significant unmet medical needs.
In addition to HLP003, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Following Phase 2 results that demonstrated statistically significant and clinically meaningful improvements from baseline, the company expects to finalize the design of the next study by the end of the third quarter of 2026. This progress highlights Helus Pharma's commitment to addressing multiple mental health conditions through its proprietary NSA platform.
Financially, Helus Pharma reported cash and cash equivalents of $166.4 million as of June 30, 2026. The company posted a net loss of $47.8 million for the quarter, compared to $24.6 million in the same period last year. Cash-based operating expenses increased to $37.5 million from $23.9 million, driven by the continued advancement of the APPROACH, EMBRACE, and EXTEND trials. The company also continues to develop HLP005, with a viable development candidate expected by the second half of 2027.
The Phase 3 data from APPROACH will be pivotal in determining the regulatory path for HLP003. If successful, HLP003 could offer a new treatment option for patients with MDD who have not responded adequately to existing therapies. The company has already received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for HLP003, which underscores its potential to address a serious condition.
Helus Pharma, formerly known as Cybin Inc., is dedicated to developing NSAs that activate serotonin pathways to promote neuroplasticity, aiming to provide durable improvements in mental health. With operations in Canada, the United States, the United Kingdom, and Ireland, the company is well-positioned to advance its pipeline. For more information, visit the company's website at www.helus.com.
The upcoming topline data in Q4 2026 will be a major catalyst for the company, potentially reshaping the treatment landscape for major depressive disorder. As the company progresses, investors and patients alike will be watching closely for the results that could bring HLP003 one step closer to market.
